tbuckley/cabot-search huggingface dataset:
Pesticides are Associated with Allergic and Non-Allergic Wheeze among Male Farmers
Authors: Jane A. Hoppin, David M. Umbach, Stuart Long, Stephanie J. London, Paul K. Henneberger, Aaron Blair, Michael Alavanja, Laura E. Beane Freeman, Dale P. Sandler
Journal: Environmental Health Perspectives (2016)

Growing evidence suggests that pesticide use may contribute to respiratory symptoms.We evaluated the association of currently used pesticides with allergic and non-allergic wheeze among male farmers.Using the 2005-2010 interview data of the Agricultural Health Study, a prospective study of farmers in North Carolina and Iowa, we evaluated the association between allergic and non-allergic wheeze and self-reported use of 78 specific pesticides, reported by ≥ 1% of the 22,134 men interviewed. We used polytomous regression models adjusted for age, BMI, state, smoking, and current asthma, as well as for days applying pesticides and days driving diesel tractors. We defined allergic wheeze as reporting both wheeze and doctor-diagnosed hay fever (n = 1,310, 6%) and non-allergic wheeze as reporting wheeze but not hay fever (n = 3,939, 18%); men without wheeze were the referent.In models evaluating current use of specific pesticides, 19 pesticides were significantly associated (p < 0.05) with allergic wheeze (18 positive, 1 negative) and 21 pesticides with non-allergic wheeze (19 positive, 2 negative); 11 pesticides were associated with both. Seven pesticides (herbicides: 2,4-D and simazine; insecticides: carbaryl, dimethoate, disulfoton, and zeta-cypermethrin; and fungicide pyraclostrobin) had significantly different associations for allergic and non-allergic wheeze. In exposure-response models with up to five exposure categories, we saw evidence of an exposure-response relationship for several pesticides including the commonly used herbicides 2,4-D and glyphosate, the insecticides permethrin and carbaryl, and the rodenticide warfarin.These results for farmers implicate several pesticides that are commonly used in agricultural and residential settings with adverse respiratory effects.
Multiplex layered immunohistochemistry to predict response of HER2-positive breast cancer patients to trastuzumab therapy.
Authors: Soon Sik Park, John Williams Gillespie, Bill James, Michael Lebowitz
Journal: Journal of Clinical Oncology (2012)

136 Background: Since only 40% of HER2-positive breast cancer patients respond to trastuzumab therapy, there is a great clinical need for a test that will better predict which patients would be responders to trastuzumab therapy. Since no single biomarker will likely improve identification of responders, this study will determine the efficacy of multiple biomarkers to predict response of patients to trastuzumab therapy. Our company has developed a protein analysis platform, layered immunohistochemistry (L-IHC), for the analysis of multiple protein biomarkers from a single FFPE tissue section while retaining the histologic orientation. L-IHC is being used to develop a companion diagnostic test in which multiple protein biomarkers are analyzed in HER2-positive breast cancer specimens to predict which patients will respond to trastuzumab therapy. Methods: In this ongoing clinical exploratory study, analysis of pretreatment archival HER2-positive FFPE breast cancer tissue sections from patients whose subsequent therapy included trastuzumab and whose response to therapy (responders and non-responders) is known was performed using L-IHC. Tissue sections were probed using a panel of 14 biomarkers along the HER2 and mTOR pathways were analyzed. In a blinded fashion to the response data, the intensity of specific biomarker signals corresponding to cancer regions on an H&amp;E was visually scored (0,1,2,3, &amp; 4+). The pattern of biomarker expression was correlated with the responder status of the patient. Results: A total of 24 responders and 9 non-responders were analyzed. The sum of four of the 14 biomarkers including p-mTOR, p-4EBP1, pERK, and HIF1-alpha discriminated the responders and non-responders. Using 7 as a cutoff, this test correctly identified 21/24 responders and 7/9 non-responders for a sensitivity of 87%, specificity of 78%, and an accuracy of 82%. Conclusions: Results of this study strongly suggests that analysis of p-mTOR, p-4EBP1, pERK, and HIF1-alpha using L-IHC improves twofold the prediction of patient response to trastuzumab compared to Her2 alone.
Follicular Lymphoma with Diffuse Large B-Cell Component At Initial Diagnosis Appears to Be Associated with a Loss of BCL2 Translocation and Inferior Progression Free Survival
Authors: Kevin Tay, Yee Siang Shew, Yu Lin Gao, Whee Sze Ong, Tiffany Tang, Richard Quek, Daryl Tan, Leonard Tan, Miriam Tao, Soo Yong Tan, Soon Thye Lim
Journal: Blood (2011)
Surveillance of tuberculosis in the WHO European Region 1995-1996
Authors: D Antoine, V Schwoebel, J Veen, M. C. Raviglione, H. L. Rieder
Journal: Eurosurveillance (1998)

The EuroTB programme for the surveillance of tuberculosis in Europe was set up in 1996 to collect, analyse, and disseminate data on tuberculosis cases notified in the World Health Organization (WHO) European Region. Following a feasibility study performed
Quantitative Analysis of Patient-Specific Lesions in Primary and Xenografted Myelodysplastic Syndromes Reveals Complex Hierarchies and Subclonal Diversity That Evolve during Disease Progression
Authors: Johann-Christoph Jann, Daniel Nowak, Janina Wittig, Florian Nolte, Stephanie Fey, Verena Nowak, Julia Obländer, Jovita Pressler, Katja Müdder, Corinna Klein, Bettina Zens, Uwe Platzbecker, Claudia Schönefeldt, Alice Fabarius, Helmut Blum, Torsten J Schulze, Claudia Haferlach, Andreas Trumpp, Wolf-Karsten Hofmann, Hind Medyouf, Maximilian Mossner
Journal: Blood (2014)
Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1
Authors: Matthew Smith, Johann De Bono, Cora Sternberg, Sylvestre Le Moulec, Stéphane Oudard, Ugo De Giorgi, Michael Krainer, Andries Bergman, Wolfgang Hoelzer, Ronald De Wit, Martin Bögemann, Fred Saad, Giorgio Cruciani, Antoine Thiery-Vuillemin, Susan Feyerabend, Kurt Miller, Nadine Houédé, Syed Hussain, Elaine Lam, Jonathan Polikoff, Arnulf Stenzl, Paul Mainwaring, David Ramies, Colin Hessel, Aaron Weitzman, Karim Fizazi
Journal: Journal of Clinical Oncology (2016)

Cabozantinib is an inhibitor of kinases, including MET and vascular endothelial growth factor receptors, and has shown activity in men with previously treated metastatic castration-resistant prostate cancer (mCRPC). This blinded phase III trial compared cabozantinib with prednisone in patients with mCRPC.Men with progressive mCRPC after docetaxel and abiraterone and/or enzalutamide were randomly assigned at a two-to-one ratio to cabozantinib 60 mg once per day or prednisone 5 mg twice per day. The primary end point was overall survival (OS). Bone scan response (BSR) at week 12 as assessed by independent review committee was the secondary end point; radiographic progression-free survival (rPFS) and effects on circulating tumor cells (CTCs), bone biomarkers, serum prostate-specific antigen (PSA), and symptomatic skeletal events (SSEs) were exploratory assessments.A total of 1,028 patients were randomly assigned to cabozantinib (n = 682) or prednisone (n = 346). Median OS was 11.0 months with cabozantinib and 9.8 months with prednisone (hazard ratio, 0.90; 95% CI, 0.76 to 1.06; stratified log-rank P = .213). BSR at week 12 favored cabozantinib (42% v 3%; stratified Cochran-Mantel-Haenszel P < .001). rPFS was improved in the cabozantinib group (median, 5.6 v 2.8 months; hazard ratio, 0.48; 95% CI, 0.40 to 0.57; stratified log-rank P < .001). Cabozantinib was associated with improvements in CTC conversion, bone biomarkers, and post-random assignment incidence of SSEs but not PSA outcomes. Grade 3 to 4 adverse events and discontinuations because of adverse events were higher with cabozantinib than with prednisone (71% v 56% and 33% v 12%, respectively).Cabozantinib did not significantly improve OS compared with prednisone in heavily treated patients with mCRPC and progressive disease after docetaxel and abiraterone and/or enzalutamide. Cabozantinib had some activity in improving BSR, rPFS, SSEs, CTC conversions, and bone biomarkers but not PSA outcomes.
PWE-222 To peg or not to peg: attitudes of healthcare professionals towards gastrostomy feeding: Abstract PWE-222 Table 1
Authors: H Penny, M Kurien, M El-Feki, C Ruse, DS Sanders
Journal: Gut (2015)

<h3>Introduction</h3> A percutaneous endoscopic gastrostomy (PEG) may be used to provide enteral nutrition to patients, when oral intake is inadequate. Evidence supports PEG feeding in patients with stroke and oropharyngeal malignancy, however no benefit has been shown in patients with advanced dementia. This study examines attitudes of healthcare professionals towards PEG insertions and whether decisions reflect current evidence. <h3>Method</h3> Consultant physicians, GPs, Nurses, Speech and language therapists (SLT), Dietitians, Junior doctors and Student doctors and nurses were invited to complete a questionnaire pertaining to four clinical cases: advanced dementia, advanced cancer with poor oral intake, dysphagic stroke and prophylactic PEG in head and neck cancer. Appropriateness of PEG insertion was questioned for these devised cases and rationale for insertion determined. <h3>Results</h3> 426/684 (62%) questionnaires were returned. 13% of participants had previously received teaching about PEG feeding. Table 1shows the proportion of healthcare professionals who would initiate feeding for each case. Consultants, dietitians and SLTs were less likely to feed in advanced dementia than nurses or students (p &lt; 0.0001), with poor prognosis and increased complications being the main rationale. 40% of all participants felt PEG insertion would prevent aspiration pneumonia in advanced dementia. In both dysphagic stroke and head and neck cancer cases, qualified staff were more likely to insert PEGs compared to students (p &lt; 0.0001), with perceived improvements in nutritional status and quality of life influencing the decision-making. <h3>Conclusion</h3> This study demonstrates that healthcare professionals have variable knowledge about the evidence base supporting gastrostomy feeding. Furthermore, we demonstrate teaching in this important area is limited. Given the increased frequency of PEG insertions, we advocate enhancing education of PEG feeding in both undergraduate and postgraduate training programmes, thereby hopefully improving patient selection. <h3>Disclosure of interest</h3> None Declared.
P-142 Experience with Aflibercept as a second line chemotherapy in metastatic colorectal cancer
Authors: E. González-Flores, B. González-Astorga, T. Delgado Ureña M, V. Conde, C. Sánchez-Toro, M. Legeren Alvarez, A. Villaescusa, F. Gálvez Montosa, J. García-García
Journal: Annals of Oncology (2016)
Nuclear Cardiology
Authors: B L Zaret, F J Wackers
Journal: New England Journal of Medicine (1993)

Evaluation of Ventricular FunctionBasic TechniquesCardiac performance, or ventricular function, can be assessed with radionuclide techniques by either of two methods. The first involves analyzing the initial transit of an intravenously administered radionuclide bolus as it traverses the central circulation. This has been called first-pass radionuclide angiocardiography, and it involves sampling for only the first 15 to 30 seconds after the injection92. The high-frequency components of the time-activity curve of radioactivity during this period are analyzed quantitatively. The radioactive indicator mixes with the blood to such an extent that the count rates of radioactivity are proportional to changes . . .
ODM-204, a novel dual inhibitor of CYP17A1 and androgen receptor for the treatment of castration-resistant prostate cancer.
Authors: Pekka Kallio, Riikka Oksala, Anu Moilanen, Reetta Riikonen, Petteri Rummakko, Chira Malmström, Mika VJ Mustonen
Journal: Journal of Clinical Oncology (2016)

230 Background: Castration-resistant prostate cancer (CRPC) is characterized by high androgen receptor (AR) expression and persistent activation of AR signaling axis by residual tissue androgens. Inhibiting AR and androgen biosynthesis together may be more effective than inhibiting either alone to treat CRPC. ODM-204 is a potent, orally administered investigational non-steroidal dual inhibitor of CYP17A1 and AR. In vivo, ODM-204 shows favourable pharmacokinetic/ pharmacodynamics (PK/PD) properties in intact mature male monkeys and strong antitumor activity in VCaP xenograft. Methods: The inhibition of CYP17A1 by ODM-204 was studied by using human testicular microsomes and adrenal cortex cell line. Potency to human AR was demonstrated in cells stably transfected with the full-length AR and androgen-responsive reporter gene constructs. PK/PD relationships were evaluated in intact male mature monkeys after single and multiple doses of ODM-204 (10-30 mg/kg/day) by measuring plasma PK after several time points and serum testosterone (T), dehydroepiandrosterone (DHEA), luteinizing hormone (LH), aldosterone, and cortisol 5 hours after the daily dose. Efficacy was further studied in VCaP xenograft in intact male nude mice treated with ODM-204, enzalutamide (enza), abiraterone (abi), or enza+abi-combination for 28 days. Results: ODM-204 binds to AR with a high affinity (Ki47 nM) and selectivity, and has a high potency towards CYP17A1 (IC 50 22 nM). In intact monkeys, ODM-204 was well tolerated and showed good oral bioavailability with linear and dose proportional pharmacokinetics. Already after a single oral dose of ODM-204, serum T and DHEA were markedly suppressed. After multiple days of dosing, LH was increased, however, changes in cortisol and aldosterone were only minimal. In VCaP xenograft model, ODM-204 showed significant antitumor activity, better than single agent enza or abi, or their combination. Conclusions: ODM-204 is a novel, dual CYP17A1 and AR inhibitor for the treatment of CRPC. A clinical phase 1/2 dose-escalation trial (NCT02344017) is ongoing in patients with mCRPC to determine PK, PD, safety and anti-tumor activity of ODM-204.
Neuroma in phantom limb syndrome: blood-pool and magnetic resonance imaging findings.
Authors: HANI ABU-JUDEH
Journal: Clinical Nuclear Medicine (2001)

From the Department of Radiology, University of Medicine and Dentistry of New Jersey, Newark, New Jersey Received for publication June 2, 2000. Accepted July 10, 2000. Correspondence: Hani H. Abu-Judeh, Department of Radiology, University of Medicine and Dentistry of New Jersey, New Jersey Medical School, 150 Bergen Street, Newark, New Jersey 07103. E-mail [email protected]
An extraperitoneal midline approach to retroperitoneal lymph node dissection to minimize bowel morbidity.
Authors: Sumeet Syan-Bhanvadia, Soroush T. Bazargani, Thomas G. Clifford, Hooman Djaladat, Anne K. Schuckman, Siamak Daneshmand
Journal: Journal of Clinical Oncology (2016)

e16042 Background: We have adopted a midline extraperitoneal approach to retroperitoneal lymph node dissection (RPLND) for non-seminomatous germ cell testicular tumor in order to decrease perioperative, especially GI, morbidity. Methods: From 2004 to 2015, 169 patients have undergone RPLND by a single surgeon (135 post-chemotherapy). As of 2010 all patients were considered for EP-RPLND except for those undergoing aortic resection, retrocrural dissection, mesenteric lymphadenectomy or liver resection. Of the remaining 119 patients, 61 consecutive patients underwent EP-RPLND. All PC cases underwent bilateral template dissection; all primary cases underwent extended ipsilateral templates. Data was prospectively collected and compared to a matched cohort of patients undergoing midline transperitoneal (TP) RPLND (2004-2010). Results: There were 61 patients in each arm; no significant differences between the EP-RPLND and TP-RPLND groups with regard to patient age (28.8 vs 30.8 years, p = 0.24). Size of retroperitoneal mass on preoperative imaging was < 2 cm, 2-5 cm and > 5 cm in 22 (24%), 14 (15%), 25 (27%) in the EP group which was not different than the TP group (p = 0.55). 4 patients in the EP group underwent caval resection. Estimated blood loss was lower in EP-RPLND patients (674 vs 888 mL, p = 0.076); there was no difference in blood transfusion (0.5 vs. 0.8 units, p = 0.2). Median LOS was lower in the EP-RPLND group at 3 days versus 7 days for TP-RPLND (p < 0.001). In the EP group there were two grade I early complications (lymph leakage and wound infection) and one patient with grade II complications (pleural effusion and blood transfusion) in the EP-RPLND group. One patient developed a late complication of lymphocele, which needed percutaneous drainage (grade III); 90-day complication rates were no different between groups (p = 0.7). Conclusions: Midline extraperitoneal RPLND can be performed safely without compromising completeness of resection or increasing perioperative complications, even in the setting of post-chemotherapy and vascular reconstruction. This approach is associated with shorter LOS that may be attributed to a decreased incidence of postoperative ileus and faster return of bowel function.
Midostaurin in Advanced Systemic Mastocytosis
Authors: Marie-Olivia Chandesris, Gandhi Damaj, Danielle Canioni, Chantal Brouzes, Ludovic Lhermitte, Katia Hanssens, Laurent Frenzel, Zoubair Cherquaoui, Isabelle Durieu, Stéphane Durupt, Emmanuel Gyan, Odille Beyne-Rauzy, David Launay, Cyril Faure, Mohamed Hamidou, Sophie Besnard, Momar Diouf, Aurélie Schiffmann, Mathilde Niault, Pierre-Yves Jeandel, Dana Ranta, Remi Gressin, Sylvain Chantepie, Stéphane Barete, Patrice Dubreuil, Philippe Bourget, Olivier Lortholary, Olivier Hermine
Journal: New England Journal of Medicine (2016)

The use of midostaurin, a multikinase inhibitor, has been associated with a response in 60% of patients with systemic mastocytosis, including mast-cell leukemia; the median overall survival was 28 months. A second, smaller trial in France showed a 71% response rate.
Taïmyr
Authors: Carrie A. Butt
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Hepatic B cell leukemia-3 promotes hepatic steatosis and inflammation through insulin-sensitive metabolic transcription factors
Authors: Nadine Gehrke, Marcus A. Wörns, Yvonne Huber, Moritz Hess, Beate K. Straub, Nadine Hövelmeyer, Ari Waisman, Yong Ook Kim, Detlef Schuppan, Peter R. Galle, Jörn M. Schattenberg
Journal: Journal of Hepatology (2016)
Loss of PIKFyve In Murine Platelets Leads to Aberrant Platelet Granule Biogenesis and a Pleomorphic Phenotype with Multiorgan Failure
Authors: Sang H. Min, Aae Suzuki, Liang Zhao, Lurong Lian, Sidney W. Whiteheart, Michael S. Marks, John K. Choi, Charles S. Abrams
Journal: Blood (2010)
Efficacy and Safety of Carfilzomib, Lenalidomide, and Dexamethasone Vs Lenalidomide and Dexamethasone in Patients with Relapsed Multiple Myeloma Based on Cytogenetic Risk Status: Subgroup Analysis from the Phase 3 Study Aspire (NCT01080391)
Authors: Hervé Avet-Loiseau, Rafael Fonseca, David Siegel, Meletios A. Dimopoulos, Ivan Spicka, Tamás Masszi, Roman Hájek, Laura Rosiñol, Vesselina Goranova-Marinova, Georgi Mihaylov, Vladimír Maisnar, Maria-Victoria Mateos, Michael Wang, Ruben Niesvizky, Albert Oriol, Andrzej Jakubowiak, Jiri Minarik, Antonio Palumbo, William Bensinger, Vishal Kukreti, Dina Ben-Yehuda, Margaret Tonda, Mihaela Obreja, Philippe Moreau
Journal: Blood (2015)
Outcome of breast cancer with symptomatic bone marrow involvement.
Authors: Carlos O Munive, Maria F Muro, Greenlandia Ferreyros, Miluska Mayuri, Joseph A. Pinto, Jhajaira Araujo, Henry Gomez
Journal: Journal of Clinical Oncology (2015)

e12611 Background: The breast cancer shows different patterns of metastasis, one of them is the bone marrow involvement whose symptomatic presentation is rare. In this study we evaluated the outcomes of a cohort of breast cancer with symptomatic bone marrow involvement (SBMI). Methods: We retrospectively evaluated 22 cases of breast cancer patients with SBMI during the period 1998-2014. Mean clinical pathological features were evaluated. The time to event endpoints were evaluated with the Kaplan Meier method. Results: The median age was 42.5 (Range: 24-64). In regard to the clinical stage (CS), 27.3% were CS II, 22.7% were CS III and 50% were CS IV. In regard to IHC biomarkers, 70% were ER+, 42.1% were PR+ and 10.5% were HER2+. Median of WBC was 6.77 x 109/L (range: 1.2-18.8); median of platelets count was 64 x 109/L (range: 4-423); median of hemoglobin was 10.5 g/dL (range: 3.9-14.2). In regard to other metastatic sites at time of SBMI, 45.5% had hepatic metastases; 45% had lung metastases; 26% had brain metastases and 10% other metastases. The median of overall survival for all patients was 11.6 months. The median time from the diagnostic to the development of symptomatic bone marrow metastases was 5.8 months; the median time of post-SBMI survival was 2.6 months. Conclusions: We observed a poor prognosis pattern in patients with SBMI with a shorter survival than reported in other series.
PET Imaging with [<sup>18</sup>F]FSPG Evidences the Role of System xc<sup>-</sup> on Brain Inflammation Following Cerebral Ischemia in Rats
Authors: Maria Domercq, Boguslaw Szczupak, Jon Gejo, Vanessa Gómez-Vallejo, Daniel Padro, Kiran Babu Gona, Frédéric Dollé, Makoto Higuchi, Carlos Matute, Jordi Llop, Abraham Martín
Journal: Theranostics (2016)

In vivo Positron Emission Tomography (PET) imaging of the cystine-glutamate antiporter (system xc -) activity with [ 18 F]FSPG is meant to be an attractive tool for the diagnosis and therapy evaluation of brain diseases.However, the role of system xc -in cerebral ischemia and its involvement in inflammatory reaction has been scarcely explored.In this work, we report the longitudinal investigation of the neuroinflammatory process following transient middle cerebral artery occlusion (MCAO) in rats using PET with [ 18 F]FSPG and the translocator protein (TSPO) ligand [ 18 F]DPA-714.In the ischemic territory, [ 18 F]FSPG showed a progressive binding increase that peaked at days 3 to 7 and was followed by a progressive decrease from days 14 to 28 after reperfusion.In contrast, [ 18 F]DPA-714 evidenced maximum binding uptake values over day 7 after reperfusion.Ex vivo immnunohistochemistry confirmed the up-regulation of system xc -in microglial cells and marginally in astrocytes.Inhibition of system xc -with sulfasalazine and S-4-CPG resulted in increased arginase (anti-inflammatory M2 marker) expression at day 7 after ischemia, together with a decrease in TSPO and microglial M1 proinflammatory markers (CCL2, TNF and iNOS) expression.Taken together, these results suggest that system xc -plays a key role in the inflammatory reaction underlying experimental stroke.